Chart Review of Repatha® in Subjects With Hyperlipidaemia (HEYMANS)

Amgen

Status: Completed

Conditions: Hypercholesterolaemia

Study type: Observational

Funder types: Industry

Identifiers

NCT02770131

20130296

Details and patient eligibility

About

Review of clinical characteristics of patients who are prescribed Repatha® and how their treatment is managed.

Enrollment: 1,986 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Adults (>18 years) Provided informed consent Initiated on Repatha® at physician's discretion, after 1st August 2015 Received at least one dose of Repatha®

Exclusion criteria

Enrolled in an interventional study of PCSK9 inhibitor within 12 weeks prior to initiation of Repatha® Received commercially available PCSK9 inhibitor within 12 weeks prior to initiation of Repatha®

Trial design

1,986 participants in 1 patient group

Group 1

Description:

To describe the clinical characteristics of subjects at initiation of Repatha® (up to 2000 subjects).